Acadia Pharmaceuticals Inc ACAD
1 target with a reported result
Releases of the last 3 yearsThe numbers ACAD said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $1.22B to $1.28B release Feb 25, 2026
Kept $1.22B to $1.28B release May 6, 2026
Raised $1.24B to $1.30B release Aug 4, 2026
Lowered $505.00M to $520.00M release Nov 4, 2026
|
– | Not reported yet | |
The company's wordsFull Year 2026 Financial Guidance (GAAP): … Total revenues of $1.22 to $1.28 billion release Feb 25, 2026 Acadia is reaffirming its 2026 guidance as first provided on February 25, 2026: … Total revenues of $1.22 to $1.28 billion release May 6, 2026 - Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million release Aug 4, 2026 - Raises 2026 DAYBUE net sales guidance to $505–$520 million; narrows NUPLAZID range and total revenue range release Nov 4, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $1.03B to $1.09B release Feb 26, 2025
Kept $1.03B to $1.09B release May 7, 2025
Lowered $665.00M to $690.00M release Aug 6, 2025
Raised $1.07B to $1.09B release Nov 5, 2025
|
$1.07B 10-K filed 2026-02-26 |
Within the range | |
The company's wordsFull Year 2025 Financial Guidance … Total Revenues (U.S. only) of $1.03 to $1.095 billion release Feb 26, 2025 Full Year 2025 Financial Guidance … Total Revenues (U.S. only) of $1.03 to $1.095 billion. release May 7, 2025 - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance release Aug 6, 2025 Acadia is updating its 2025 guidance: … Total Revenues in the range of $1.070 to $1.095 billion, compared with the prior guidance range of $1.045 to $1.095 billion * . release Nov 5, 2025 | ||||
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
- Revenue, Fiscal 2024 (ended Dec 31, 2024): said $600.00M to $610.00M, reported $957.80M. The company's words
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-27), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ACAD/export.csv") into a cell.